Daly, Jennifer S.Giehl, Theodore J.Brown, Neal C.Zhi, ChengxinWright, George E.Ellison, Richard T. III2022-08-232022-08-232000-08-012008-02-29Antimicrob Agents Chemother. 2000 Aug;44(8):2217-21. doi:10.1128/AAC.44.8.2217-2221.2000. <a href="http://dx.doi.org/10.1128/AAC.44.8.2217-2221.2000" target="_blank">Link to article on publisher's site</a>0066-4804 (Print)10.1128/AAC.44.8.2217-2221.200010898708https://hdl.handle.net/20.500.14038/38993The 6-anilinouracils are novel dGTP analogs that selectively inhibit the replication-specific DNA polymerase III of gram-positive eubacteria. Two specific derivatives, IMAU (6-[3'-iodo-4'-methylanilino]uracil) and EMAU (6-[3'-ethyl-4'-methylanilino]uracil), were substituted with either a hydroxybutyl (HB) or a methoxybutyl (MB) group at their N3 positions to produce four agents: HB-EMAU, MB-EMAU, HB-IMAU, and MB-IMAU. These four new agents inhibited Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Time-kill assays and broth dilution testing confirmed bactericidal activity. These anilinouracil derivatives represent a novel class of antimicrobials with promising activities against gram-positive bacteria that are resistant to currently available agents, validating replication-specific DNA polymerase III as a new target for antimicrobial development.en-US<p>Publisher PDF posted as allowed by the publisher's author rights policy at http://journals.asm.org/site/misc/ASM_Author_Statement.xhtml.</p>Anti-Bacterial AgentsDNA Polymerase IIIEnterococcusEnzyme InhibitorsGram-Positive BacteriaHumansMicrobial Sensitivity TestsStaphylococcus aureusUracilImmunology and Infectious DiseaseImmunoprophylaxis and TherapyMedicinal Chemistry and PharmaceuticsJournal Articlehttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1181&amp;context=oapubs&amp;unstamped=1https://escholarship.umassmed.edu/oapubs/182441947oapubs/182